Biotech Values

[blackcat]

Including the PML cases which slowed Ty uptake somewhat, and the Euro vacation season which impacted it, I'm still not sure you could say "tysabri is growing a little" when it comes in at a 172% gain.

"Much of the income gain came from significant sales gains of the company’s lead multiple sclerosis drug Avonex. The drug generated $573 million in sales, a 26 percent gain.

MS drug Tysabri enjoyed a 172 percent sales increase, hitting $171 million for the quarter."